

# Hypoxic ischaemic encephalopathy in newborns

Recognition, monitoring and early management

---

JUNE 2024



The information in this document should not replace a clinician's professional judgement.

#### Agency for Clinical Innovation

1 Reserve Road St, Leonards NSW 2065  
Locked Bag 2030, St Leonards NSW 1590

Phone: +61 2 9464 4666 | Email: [aci-info@health.nsw.gov.au](mailto:aci-info@health.nsw.gov.au) | Web: [aci.health.nsw.gov.au](http://aci.health.nsw.gov.au)

Further copies of this publication can be obtained from the Agency for Clinical Innovation website at [aci.health.nsw.gov.au](http://aci.health.nsw.gov.au)

Disclaimer: Content within this publication was accurate at the time of publication.

© State of New South Wales (Agency for Clinical Innovation) 2024. Creative Commons Attribution-No Derivatives 4.0 licence. For current information go to: [aci.health.nsw.gov.au](http://aci.health.nsw.gov.au). The ACI logo and cover image are excluded from the Creative Commons licence and may only be used with express permission.

<b>Title</b>	<i>Hypoxic ischaemic encephalopathy in newborns – recognition, monitoring and early management: Clinical practice guide</i>		
<b>Replaces</b>	<i>May 2023. Hypoxic ischaemic encephalopathy in newborns – recognition, monitoring and early management: Clinical practice guide</i>		
<b>Revised</b>	May 2024. Updated references to the newborn encephalopathy assessment tool and expansion of the sudden unexpected postnatal collapse to included exclusion criteria.		
<b>Next review</b>	2029		
<b>Produced by</b>	Maternity and Neonatal Network		
<b>Preferred citation</b>	NSW Agency for Clinical Innovation. <i>Hypoxic ischaemic encephalopathy in newborns – recognition, monitoring and early management: Clinical practice guide</i> . Sydney: ACI; 2024		
<b>Cover image credit</b>	<a href="https://www.shutterstock.com">Shutterstock.com</a>		
TRIM ACI/D23/2098	SHPN (ACI) 240328	ISBN 978-1-76023-854-4	ACI_6878 [06/24]

# Contents

At a glance	1
Introduction	2
General principles of management of newborns at risk of HIE	3
Clinical management	4
Recognition and Newborn Encephalopathy Pathway	4
Assessment (including Assessment of Encephalopathy Monitoring Tool)	6
Criteria for Therapeutic hypothermia	9
Therapeutic hypothermia -initial management	10
Care of the family	13
Reporting	14
References	16
Appendix: Changes in guidance since 2010 NSW Health Policy Directive PD 2010: 006	19
Acknowledgements	20

# At a glance

This clinical practice guide provides guidance on recognition, monitoring and early management of newborns with hypoxic ischaemic encephalopathy (HIE) who may benefit from therapeutic hypothermia (cooling). Therapeutic hypothermia has been found to be safe for term and late preterm infants (≥35 weeks gestation) with moderate or severe HIE.

## Clinical management of newborns with HIE



### Recognition

Use the [Newborn Encephalopathy Pathway](#) to identify encephalopathy during labour and birth, and manage appropriately



### Assessment and monitoring of encephalopathy severity

Use the [Newborn Encephalopathy Assessment Tool](#) to assess the severity of encephalopathy in newborns every hour in the first six hours of birth



### Therapeutic hypothermia

Initiate therapeutic hypothermia for newborns who meet **all of the three** criteria:

GA ≥35 weeks and ≥1,800g and <6 hours old

**AND**

Evidence of severe acidosis or depression at birth, with any ONE of:

- pH <7.00 or a BE equal to or worse than -12mmol/L on any cord or newborn blood gas in first hour
- Apgar score <6 at 10 minutes
- Ongoing resuscitation (positive pressure ventilation or cardiac massage) for ≥10 minutes

**AND**

Presence of moderate/severe encephalopathy with any **ONE** of:

- three or more moderate or severe features of encephalopathy ([Sarnat criteria](#)) identified at any time from 1 to 6 hours of life

**OR**

- two moderate or severe features of encephalopathy and abnormal aEEG (e.g. aEEG lower margin <5µV for >1 hour)

**OR**

- Seizures (witnessed by a medical officer/nurse/midwife or seen on aEEG/EEG)

**For newborns who meet two or more criteria for moderate or severe encephalopathy OR seizures at any time from one to six hours of life:**

- consider therapeutic hypothermia
- request senior medical review
- seek NETS advice.

If uncertain about the need for therapeutic hypothermia, **transfer the newborn to a neonatal intensive care unit.**

**Contraindications for therapeutic hypothermia**

No absolute contraindications but relative contraindications include:

- uncontrolled bleeding
- uncontrolled severe hypoxia due to persistent pulmonary hypertension
- imminent end of life care planned.

# Introduction

**This clinical practice guide provides guidance on recognition, monitoring and early management of newborns with hypoxic ischaemic encephalopathy who may benefit from therapeutic hypothermia. The guide replaces the NSW Health Policy Directive PD2010 006: Whole Body Cooling – Neonates Suspected Moderate or Severe Hypoxic Ischaemic Encephalopathy (HIE).<sup>1</sup> Changes since PD2010 006 are documented in [Appendix 1](#).**

## Background

Hypoxic ischaemic encephalopathy (HIE) is a type of neonatal encephalopathy caused by systemic hypoxaemia and/or reduced cerebral blood flow resulting from an acute peripartum event.<sup>2</sup> It can be the result of perinatal and/or neonatal asphyxia.<sup>3</sup> HIE is classified as mild, moderate or severe based on the Sarnat score for encephalopathy.<sup>4</sup>

Evidence from high-quality, multi-centred trials and meta-analysis supports that therapeutic hypothermia is safe for term and late preterm infants ( $\geq 35$  weeks gestation) with moderate or severe HIE. It reduces the risk of death or disability at 18 to 22 months if commenced within six hours of birth.<sup>5-10</sup> In 2020, 358 (6.0%) of the Australian and New Zealand Neonatal Network (ANZNN) registrants born at more than 34 weeks gestation received therapeutic hypothermia.<sup>11</sup>

## Intended audience

This guide is intended for clinicians in all facilities caring for newborns.

## Methods

The NSW Health Hypoxic Ischaemic Encephalopathy Expert Advisory Group was established in March 2021 at the request of the Clinical Excellence Commission (CEC) and the Agency for Clinical Innovation (ACI) to standardise the definition, documentation and clinical assessment of neonates with neonatal encephalopathy, and update the NSW Health Policy Directive PD2010.006. The advisory group consisted of senior medical, nursing and midwifery clinicians with expertise in obstetrics, neonatology and paediatrics from NSW, together with observers from Victoria and the Australian Capital Territory (ACT), and was supported by executive sponsors and staff from the CEC and the ACI.

An evidence review was used to inform this update, and a report of this group was published as the NSW Consensus Statement: Newborn Hypoxic Ischaemic Encephalopathy (HIE).<sup>12</sup>

# General principles of management of newborns at risk of HIE

## Identify all newborns at risk of HIE at birth and undertake ongoing monitoring

- Identify all newborns at risk of HIE at birth and commence monitoring using the [Newborn Encephalopathy Pathway](#) and [Newborn Encephalopathy Assessment Tool](#).

## Prioritise resuscitation and stabilisation before commencing therapeutic hypothermia

- Identify acute peripartum events for HIE (refer to [Box 1](#)).<sup>13</sup>
- Ensure appropriate resuscitation and stabilisation of the newborn, paying close attention to airway, breathing, circulation and glucose levels before considering therapeutic cooling.<sup>14</sup>
- Always avoid hyperthermia. A core temperature of >37.5C increases the risk of death and disability.<sup>15</sup>
- Prioritise attention to basic pathophysiology supports for all newborns who are at risk of HIE, including any cardio-respiratory and fluids and glucose needs.<sup>7,16</sup> Exercise caution with fluid boluses.<sup>17,18</sup>
- Therapeutic hypothermia is an adjunct therapy and must only be considered after initial resuscitation and stabilisation.<sup>1</sup>
- The ability to provide therapeutic hypothermia should not influence decisions about cessation of resuscitation attempts at birth.<sup>19</sup>

## Do not commence therapeutic hypothermia without a Newborn and Paediatric Emergency Transport Service consultation

- Initiate early discussion with a neonatologist or Newborn and Paediatric Emergency Transport Service (NETS) for all newborns who meet two or more criteria of moderate or severe encephalopathy or seizures at any time from one to six hours of birth (see [Criteria for Therapeutic Hypothermia](#)).
- Therapeutic hypothermia must **not** be commenced without discussion with NETS and a tertiary centre neonatologist.
- All newborns for whom therapeutic hypothermia is commenced should be transferred to a neonatal intensive care unit (NICU) for continuing management.<sup>20</sup>
- If the need for therapeutic hypothermia is uncertain (e.g. if the newborn has two, but not three, features of moderate or severe encephalopathy), it may also be appropriate to transfer the newborn to a NICU for further assessment, including electroencephalogram (EEG) or amplitude integrated EEG (aEEG) monitoring.

# Clinical management

## Recognition: The Newborn Encephalopathy Pathway


- Acute peripartum events (see Box 1) for encephalopathy should be identified during labour and birth<sup>21</sup> and managed appropriately.<sup>22</sup>

### Box 1: Examples of acute peripartum events

- Uterine rupture
- Placental abruption
- Cord prolapse
- Maternal collapse
- Fetal exsanguination, e.g. with vasa praevia
- Amniotic fluid embolism
- Severe maternal hypotension
- Prolonged labour with transverse arrest
- Prolonged shoulder dystocia
- Difficult instrumental delivery

- For newborns with acute peripartum risk factors, abnormal 'Red Zone' fetal heart monitoring or active resuscitation at birth, perform
  - paired cord blood gases or
  - a neonatal blood gas in the first hour of life (where paired cord gases are unable to be collected).
- Follow the Newborn Encephalopathy Pathway ([Figure 1](#)) for all newborns with any of the following:
  - pH <7.1mmHg
  - Base Excess (BE) equal to or worse than -12mmol/L
  - Apgar score <7 at 5 minutes
  - Lactate ≥8mmol/L
  - Ongoing resuscitation for ≥10 minutes.
- The Newborn Encephalopathy Pathway may also be used to monitor and assess newborns who experience a sudden unexpected postnatal collapse (SUPC) in the birthing unit or post-natal environment.<sup>23</sup> Other possible causes of collapse (e.g. sepsis, metabolic or intracranial haemorrhage) should be considered and/or excluded.

Figure 1: Newborn Encephalopathy Pathway



\*Examples of acute peripartum risk factors include uterine rupture, placental abruption, cord prolapse, fetal exsanguination from vasa praevia, shoulder dystocia, maternal collapse.

†Resuscitation defined as need for: **positive pressure ventilation** OR **cardiac massage** (excludes known surgical infants requiring planned intubation).



## Assessment and monitoring

### Monitor airways, breathing, circulation, glucose and temperature

- Admit to neonatal unit for close observation and encephalopathy, monitoring:
  - all ‘Red Pathway’ newborns
  - ‘Yellow Pathway’ newborns if concerned about lethargy, irritability, poor feeding, etc.

(See [Newborn Encephalopathy Pathway](#) for Red Pathway and Yellow Pathway criteria.)

- Assess airway, breathing, circulation and glucose
- Monitor respiratory rate, oxygen saturation, heart rate, temperature, blood pressure and glucose
- Monitor blood gases as required for clinical condition
- Monitor temperature hourly. Increase frequency if indicated by clinical condition
- Target:
  - Oxygen saturation: 91%–95%, when receiving supplemental oxygen
  - Partial pressure of carbon dioxide (PaCO<sub>2</sub>): 35–45mmHg for mechanically ventilated patients
  - Mean blood pressure: 40-50mmHg (consider inotropes for low blood pressure)
  - Blood glucose: 3–7mmol/L
  - Temperature: 36.5°C to 37.0°C (unless therapeutic hypothermia has commenced).

- Always avoid hyperthermia, as temperature >37.5°C increases the risk of morbidity and mortality.


Note: Blood glucose and temperature targets differ from the Standard Neonatal Observation Chart (SNOC) targets due to greater vulnerability of this cohort. Altered SNOC calling criteria may be required.

### Assess newborns at high risk of encephalopathy using the [Newborn Encephalopathy Assessment Tool](#) every hour in the first six hours of birth



- The level of encephalopathy cannot be accurately assessed during resuscitation or while a newborn is either critically hypoxic or hypotensive. Encephalopathy should be assessed as soon as possible after the newborn has stabilised.
- Hourly neurological assessment from one to six hours of life is recommended because of the evolving nature of HIE in the first hours after birth.<sup>8</sup> Over time some newborns may deteriorate and others improve and so therapeutic hypothermia must be considered for all newborns who meet criteria at any time in the first six hours after birth, even if their condition subsequently improves.<sup>24</sup>
- Contact NETS for advice for all newborns with evidence of two or more features of moderate or severe encephalopathy or seizures at any time from one to six hours of life.
- Newborns with mild encephalopathy may have some normal features (e.g. normal posture, tone). If present, these should be documented as normal.

- Consider alternate and additional diagnoses (e.g. subgaleal haemorrhage, sepsis other central and peripheral nervous system disorders, metabolic syndromes, cardiovascular abnormalities). Consider investigations as per the [Queensland Health HIE clinical features investigations and management](#).<sup>4</sup>
- Newborns who require sedation (e.g. opiates) or muscle relaxation (e.g. pancuronium, vecuronium) for management of severe respiratory illness require careful assessment, including neurological examination, before initiating muscle relaxation and amplitude-integrated electroencephalography (aEEG) or electroencephalography (EEG) monitoring in a NICU to assess for evidence of encephalopathy or seizures.<sup>10</sup>
- Anticonvulsant medications can make assessment of encephalopathy more difficult. If there is concern that the newborn may be having subtle or uncertain seizures, consider discussing with a neonatologist before commencing anticonvulsant medications.
- A video demonstrating the neurological examination of a baby with suspected HIE can be found at [Scottish Neuroprotection Care Pathway \(NCP\) for Infants with Hypoxic-Ischaemic Encephalopathy \(HIE\)](#).<sup>25</sup> This site also provides useful videos on supporting communication skills with parents.
- Consider aEEG monitoring or a formal EEG. Starting therapeutic hypothermia should not be delayed while waiting for these investigations.

Figure 2: Newborn encephalopathy assessment tool



SMR060998

 <p><b>NSW Health</b></p>	FAMILY NAME		MRN							
	GIVEN NAME		<input type="checkbox"/> MALE <input type="checkbox"/> FEMALE							
Facility:	D.O.B. ____/____/____	M.O.								
ADDRESS										
<b>NEWBORN ENCEPHALOPATHY ASSESSMENT TOOL</b>										
LOCATION / WARD										
COMPLETE ALL DETAILS OR AFFIX PATIENT LABEL HERE										
Clinicians are recommended to assess babies at high risk of encephalopathy using the Newborn Encephalopathy Assessment Tool every hour in the six hours following birth or until therapeutic hypothermia commences.										
<b>Modified Sarnat Criteria</b>										
Assess neonatal signs against each criterion (N = Normal / MILD = Mild / MOD = Moderate / S = Severe / or N/A = Not Available)										
Assessment Criteria	Encephalopathy Severity				Hours post birth Record severity of each criterion hourly (N, MILD, MOD, S or N/A)					
	Normal (N)	Mild (MILD)	Moderate (MOD)	Severe (S)	0-1 hrs	1-2 hrs	2-3 hrs	3-4 hrs	4-5 hrs	5-6 hrs
<b>Alertness / Level of consciousness</b>	Alert, Arouses appropriately	Hyperalert	Lethargic, Difficulty waking	Stupor or coma						
<b>Spontaneous activity</b>	Normal	Normal or increased	Decreased activity	No activity						
<b>Posture</b>	Normal	Normal	Distal flexion*	Decerebrate†						
<b>Tone</b>	Normal	Normal or increased tone in limbs or trunk	Hypotonia (focal or general) in limbs, trunk or neck	Flaccid						
<b>Suck reflex</b>	Normal	Normal or incomplete suck or biting	Weak suck	Absent						
<b>Moro reflex</b>	Normal	Exaggerated, low threshold	Incomplete	Absent						
<b>Autonomic</b>	Pupils equal/reactive, normal HR, normal RR	Pupils equal/reactive, tachycardia, normal RR	Pupils constricted or bradycardia or periodic/irregular breathing	Pupils dilated or deviated, or variable HR or apnoea						
<b>Total moderate or severe features</b>										
<b>Seizures (tick if observed)</b>										
<b>Date and time of assessment</b>										
<b>Clinician signature and designation (hourly)</b>										
<b>Telehealth / Video assessment (tick if undertaken)</b>										
<b>Request Senior Medical Review, discuss with Tertiary Centre Neonatologist/NETS Consultant and consider therapeutic hypothermia if the baby has 2 or more features of moderate or severe encephalopathy OR has seizures at any time from 1 to 6 hours post birth</b>										
* Thumb flexed under fingers or decorticate - arms flexed/legs extended † arms and legs extended or sustained tonic postures Reference: NSW Agency for Clinical Innovation. Hypoxic ischaemic encephalopathy in newborns – recognition, monitoring and early management: Clinical Practice Guide. Sydney: ACI; 2023										

NEWBORN ENCEPHALOPATHY ASSESSMENT TOOL SMR060.998

Holes Punched as per AS2828.1: 2019

BINDING MARGIN - NO WRITING

NO WRITING

Page 1 of 1

## Criteria for therapeutic hypothermia for newborns with HIE

All of the following three criteria (Table 2) must be met for the newborn to be eligible for therapeutic hypothermia.

**Table 2: Criteria for therapeutic hypothermia**

<b>1. GA ≥35 weeks and ≥1,800g and &lt;6 hours old</b>
AND
<b>2. Evidence of severe acidosis or depression at birth, with any ONE of:</b>
<ul style="list-style-type: none"> <li>• pH &lt;7.00 or a BE equal to or worse than -12mmol/L on any cord or newborn blood gas in first hour</li> <li>• Apgar score &lt;6 at 10 minutes</li> <li>• Ongoing resuscitation (positive pressure ventilation or cardiac massage) for ≥10 minutes</li> </ul>
AND
<b>3. Presence of moderate/severe encephalopathy with any ONE of:</b>
<ul style="list-style-type: none"> <li>• three or more moderate or severe features of encephalopathy (Sarnat criteria) identified at any time from 1 to 6 hours of life</li> </ul>
OR
<ul style="list-style-type: none"> <li>• two moderate or severe features of encephalopathy and abnormal aEEG (e.g. aEEG lower margin &lt;5µV for &gt;1 hour)</li> </ul>
OR
<ul style="list-style-type: none"> <li>• Seizures (witnessed by a medical officer/nurse/midwife or seen on aEEG/EEG)</li> </ul>
<b>Therapeutic hypothermia may also be considered for newborns with moderate or severe encephalopathy AND other features of hypoxia/ischaemia, including:</b>
<ul style="list-style-type: none"> <li>• pH 7-7.1, Apgar &lt;7 at 5 mins or lactate &gt;8mmol/L in the first hour</li> </ul>
OR
<ul style="list-style-type: none"> <li>• sudden unexpected post-natal collapse with pH &lt;7.1 where the cause appears to be asphyxiation and other possible causes of collapse (e.g. sepsis, metabolic, intracranial haemorrhage) have been considered and/or excluded</li> </ul>
<b>CONTRAINDICATIONS</b>
There are no absolute contraindications to therapeutic hypothermia; however, relative contraindications include:
<ul style="list-style-type: none"> <li>• uncontrolled bleeding</li> <li>• uncontrolled severe hypoxia due to persistent pulmonary hypertension</li> <li>• imminent end of life care planned.</li> </ul>

- Request Senior Medical Review, discuss with a tertiary centre neonatologist/NETS consultant and consider therapeutic hypothermia for all newborns who meet two or more criteria of moderate or severe encephalopathy (e.g. decreased lethargy, decreased activity, decreased muscle tone, abnormal postures or reflexes, weak or absent suck) OR seizures at any time from one to six of life (see [Criteria for therapeutic hypothermia](#)).
- If the need for therapeutic hypothermia is uncertain (e.g. if newborn has two, but not three, features of moderate or severe encephalopathy), it may be appropriate to transfer the newborn to a NICU for further assessment, including aEEG/EEG monitoring.
- There is insufficient evidence from clinical trials to provide clear guidance for several subgroups of newborns, including:
  - newborns with pH 7 to 7.1, Apgar <7 at 5 minutes or lactate >8mmol/L in the first hour of life<sup>26</sup>
  - Sudden Unexpected Postnatal Collapse (SUPS) in the newborn period (usually <48 hours)<sup>27, 28</sup>
  - newborns with borderline criteria, e.g. born at 34 weeks gestation, birth weight 1,750g-1,880g, encephalopathy or seizures identified at 6-12 hours of life.
- Therapeutic hypothermia may be considered on a case-by-case basis for these newborns after discussion with a tertiary centre neonatologist. However, it should only be commenced the potential benefits outweigh the risks.
- For newborns with SUPC, therapeutic hypothermia (if considered appropriate) must be commenced within six hours of the SUPC episode.<sup>27, 28</sup>

## Therapeutic hypothermia – initial management

### General principles

- Therapeutic hypothermia must not be commenced without discussion with NETS and with a tertiary centre neonatologist.
- The decision to provide therapeutic hypothermia must be made within the first six hours after birth and should be initiated as soon as possible after this decision has been made.
- Attention must be paid to other aspects of care for all newborns who are at risk of HIE, including cardio-respiratory, intravenous fluids and glucose needs. Caution must be exercised with fluid boluses outside of blood products. If the infant requires respiratory support, normal humidifier settings should be used.
- Active bleeding should be investigated and therapy provided, where needed. If there is no active bleeding, therapeutic hypothermia should not be delayed while waiting for coagulation investigations.
- Further information on early management can be found in the [Hypoxic Ischaemic Encephalopathy in the Newborn - NETS Practice Guideline](#).<sup>29</sup>

## Temperature monitoring and therapeutic hypothermia ('cooling') methods


[Refer to Figure 3 – Therapeutic hypothermia flowchart](#)

- Cardio-respiratory monitoring with continuous rectal temperature monitoring is recommended.
  - If continuous rectal monitoring is not available, intermittent axillary temperatures should be performed every 15 minutes (using a low reading thermometer).
  - Place nil by mouth.
  - Active therapeutic hypothermia can also be provided using a Total Body Therapeutic Hypothermia System ('cooling blanket'). Use local protocols if a Total Body Therapeutic Hypothermia System is available.
  - Observation and documentation of skin condition should occur every 15 minutes with active therapeutic hypothermia.<sup>30</sup>
- Consider stopping therapeutic hypothermia before 72 hours in consultation with the neonatologist if the following occur:
    - life-threatening coagulopathy
    - uncontrolled pulmonary hypertension
    - pathological cardiac arrhythmia requiring treatment (not sinus bradycardia)
    - deterioration that leads to redirection to end-of-life care based on discussions between the family, treating team and the neonatologist.

## Considerations

- If the newborn's temperature drops below 33.5°C:
  - During passive cooling: commence low radiant heater to maintain rectal or axillary temperature within target range.
  - Active cooling: remove one or both cool packs and, if necessary, turn on low radiant heater to maintain temperature within target range.
- If the newborn develops signs of distress or shivering that results in difficulties maintaining temperature, consider appropriate pharmacological support in consultation with a neonatologist.

**Figure 3: Therapeutic Hypothermia ('Cooling') Pathway**



## Care of the family

- Parents of newborns with HIE experience trauma both from the birth and from their concern about their baby and need for therapeutic hypothermia treatment.
- Face-to-face meetings with clinicians with clear, compassionate and transparent communication about their newborn's condition and need for therapeutic hypothermia, together with encouraging parental involvement, can help to reduce this trauma.<sup>31</sup>
- Provide parent information sheet on Therapeutic Hypothermia ('cooling') to Protect Newborns with Hypoxic Ischaemic Encephalopathy (HIE).
- Advise/reassure parents about their newborn's appearance and that they will feel cool to touch.
- Provide opportunities to bond by encouraging parents to provide care, e.g. nappy changes.
- Discuss and encourage breast milk expression.
- Provide immunosupportive oral care.
- Separation or isolation from their newborn may be a trigger for some parents, including Aboriginal families and refugees. Identify parents and families that may require additional support and provide referral early in the admission.
- Provide families with information about transfer, hospital name and location, contact numbers.
- A video resource on 'Supporting Communication Skills' (Video 2) can be found at [Scottish Neuroprotection Care Pathway \(NCP\) for Infants with Hypoxic-Ischaemic Encephalopathy \(HIE\)](#).<sup>25</sup> This video is designed to assist thinking about how and what you might say during early conversations with parents of a baby with suspected HIE.




# Reporting

Reporting processes should be in place to monitor incidence of newborns with moderate or severe encephalopathy (see [Figure 4](#)).

- Birthing services to complete an incident management system (ims+) report for all newborns  $\geq 35$  weeks gestation identified with high risk of neonatal encephalopathy following birth, including newborns with:
  - cord pH  $< 7.0$
  - BE equal to or worse than  $-12$  mmol/L
  - Apgar score  $< 6$  at 10 minutes
  - ongoing need for resuscitation for  $\geq 10$  minutes.
- Neonatal services to complete an incident management system (ims+) report (or addition to a previously submitted ims+ report) for newborns who develop:
  - moderate or severe HIE
  - who receive treatment with therapeutic hypothermia.
- Reporting for newborns born in a private hospital should occur through similar clinical governance systems within the newborn's hospital of birth.
- Serious incidents, including term newborns diagnosed with severe HIE or who receive therapeutic hypothermia, should be notified to the Ministry of Health via a Reportable Incident Brief in accordance with [NSW Health Policy Directive, Incident Management PD2020\\_047](#) [32 for all newborns born in NSW](#).

Figure 4: Reporting process for newborns with moderate or severe encephalopathy



## References

1. NSW Health. Whole body cooling - Neonates suspected moderate or severe hypoxic ischaemic encephalopathy (HIE). Sydney: NSW Health; 2010 [cited April 2021]. Available from: [https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/PD2010\\_006.pdf](https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/PD2010_006.pdf)
2. Allen KA, Brandon DH. Hypoxic ischaemic encephalopathy: pathophysiology and experimental treatments. *Newborn and Infant Nursing Reviews*. 2011;11(3):125-33. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171747/> DOI: 10.1053/j.nainr.2011.07.004
3. Schump EA. Neonatal encephalopathy: current management and future trends. *Crit Care Nurs Clin North Am*. 2018 Dec;30(4):509-21. Available from: <https://www.sciencedirect.com/science/article/abs/pii/S0899588518309778?via%3Dihub> DOI: 10.1016/j.cnc.2018.07.007
4. Health Q. Queensland Clinical Guidelines: hypoxic-ischaemic encephalopathy (HIE). Queensland: Queensland Health; 2018 [cited April 2021]. Available from: [https://www.health.qld.gov.au/\\_data/assets/pdf\\_file/0014/140162/g-hie.pdf](https://www.health.qld.gov.au/_data/assets/pdf_file/0014/140162/g-hie.pdf)
5. Jacobs SE, Berg M, Hunt R, et al. Cooling for newborns with with hypoxic ischaemic encephalopathy. *Cochrane Database of Systematic Reviews*. 2013. Available from: <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003311.pub3/abstract> DOI: 10.1002/14651858.CD003311.pub3
6. Laptok AR. Therapeutic hypothermia for preterm infants with hypoxic-ischemic encephalopathy: how do we move forward? *J Pediatr*. 2017 Apr;183:8-9. Available from: [https://www.jpeds.com/article/S0022-3476\(16\)31569-4/pdf](https://www.jpeds.com/article/S0022-3476(16)31569-4/pdf) DOI: 10.1016/j.jpeds.2016.12.074
7. Chiang MC, Jong YJ, Lin CH. Therapeutic hypothermia for neonates with hypoxic ischemic encephalopathy. *Pediatr Neonatol*. 2017 Dec;58(6):475-83. Available from: [https://www.pediatr-neonatology.com/article/S1875-9572\(17\)30175-4/pdf](https://www.pediatr-neonatology.com/article/S1875-9572(17)30175-4/pdf) DOI: 10.1016/j.pedneo.2016.11.001
8. Jacobs SE, Morley CJ, Inder TE, et al. Whole-body hypothermia for term and near-term newborns with hypoxic-ischemic encephalopathy: a randomized controlled trial. *Arch Pediatr Adolesc Med*. 2011 Aug;165(8):692-700. Available from: [https://jamanetwork.com/journals/jamapediatrics/articlepdf/1107569/poa15012\\_692\\_700.pdf](https://jamanetwork.com/journals/jamapediatrics/articlepdf/1107569/poa15012_692_700.pdf) DOI: 10.1001/archpediatrics.2011.43
9. Jia W, Lei X, Dong W, et al. Benefits of starting hypothermia treatment within 6 h vs. 6-12 h in newborns with moderate neonatal hypoxic-ischemic encephalopathy. *BMC Pediatr*. 2018 Feb 12;18(1):50. Available from: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809807/pdf/12887\\_2018\\_Article\\_1013.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809807/pdf/12887_2018_Article_1013.pdf) DOI: 10.1186/s12887-018-1013-2
10. Wachtel EV, Verma S, Mally PV. Update on the current management of newborns with neonatal encephalopathy. *Curr Probl Pediatr Adolesc Health Care*. 2019 Jul;49(7):100636. Available from: <https://www.sciencedirect.com/science/article/abs/pii/S1538544219300732?via%3Dihub> DOI: 10.1016/j.cppeds.2019.07.001
11. Australian and New Zealand Neonatal Network (ANZNN). Report of the Australian and New Zealand Neonatal Network. Sydney: University of New South Wales; 2020. Available from: <https://anznn.net/annualreports>

12. Clinical Excellence Commission (CEC). NSW consensus statement: Newborn hypoxic ischaemic encephalopathy (HIE). Sydney: CEC; 2021 [cited April 2021]. Available from: [https://aci.health.nsw.gov.au/\\_data/assets/pdf\\_file/0006/804534/CEC-Consensus-Statement-HIE.pdf](https://aci.health.nsw.gov.au/_data/assets/pdf_file/0006/804534/CEC-Consensus-Statement-HIE.pdf)
13. Rossi AC, Prefumo F. Antepartum and intrapartum risk factors for neonatal hypoxic-ischemic encephalopathy: a systematic review with meta-analysis. *Curr Opin Obstet Gynecol*. 2019 Dec;31(6):410-7. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/31567446> DOI: 10.1097/GCO.0000000000000581
14. Clinical Excellence Commission (CEC). Maternity - Resuscitation of the Newborn Infant. Sydney: CEC; 2018 [cited April 2021]. Available from: [https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/GL2018\\_016.pdf](https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/GL2018_016.pdf)
15. Laptok A, Tyson J, Shankaran S, et al. Elevated temperature after hypoxic-ischemic encephalopathy: risk factor for adverse outcomes. *Pediatrics*. 2008 Sep;122(3):491-9. Available from: <https://publications.aap.org/pediatrics/article/122/3/491/72312/Elevated-Temperature-After-Hypoxic-Ischemic> DOI: 10.1542/peds.2007-1673
16. New Zealand Child and Youth Clinical Networks. Newborn Clinical Network. Neonatal Encephalopathy Consensus Statement. New Zealand: New Zealand Child and Youth Clinical Networks; 2019 [cited April 2021]. Available from: <https://www.starship.org.nz/guidelines/neonatal-encephalopathy-consensus-statement-from-the-newborn-clinical/>
17. Prempunpong C, Efanov I, Sant'Anna G. The effect of the implementation of therapeutic hypothermia on fluid balance and incidence of hyponatremia in neonates with moderate or severe hypoxic-ischaemic encephalopathy. *Acta Paediatr*. 2013;102(11):e507-e13. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/apa.12362>
18. Kecskes Z, Healy G, Jensen A. Fluid restriction for term infants with hypoxic-ischaemic encephalopathy following perinatal asphyxia. *The Cochrane database of systematic reviews* 2005. Available from: <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004337.pub2/full> DOI: 10.1002/14651858.CD004337
19. Victoria SC. Encephalopathy in neonates. Victoria: Safer Care; 2018 [cited August 2022]. Available from: <https://www.bettersaferecare.vic.gov.au/clinical-guidance/neonatal-encephalopathy-in-neonates>
20. Shipley L, Mistry A, Sharkey D. Outcomes of neonatal hypoxic-ischaemic encephalopathy in centres with and without active therapeutic hypothermia: a nationwide propensity score-matched analysis. *Archives of Disease in Childhood - Fetal and Neonatal Edition*. 2022;107(1):6. Available from: <http://fn.bmj.com/content/107/1/6.abstract> DOI: 10.1136/archdischild-2020-320966
21. Aslam S, Strickland T, Molloy EJ. Neonatal Encephalopathy: Need for Recognition of Multiple Etiologies for Optimal Management. *Front Pediatr*. 2019;7:142. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/31058120> DOI: 10.3389/fped.2019.00142

22. Shankaran S, Laptook AR, McDonald SA, et al. Acute perinatal sentinel events, neonatal brain injury pattern and outcome of infants undergoing a trial of hypothermia for neonatal hypoxic-ischemic encephalopathy. *J Pediatr*. 2017;180:275-8. Available from: <https://pubmed.ncbi.nlm.nih.gov/27776752/> DOI: 10.1016/j.jpeds.2016.09.026
23. Pejovic NJ, Herlenius E. Unexpected collapse of healthy newborn infants: risk factors, supervision and hypothermia treatment. *Acta Paediatr*. 2013 Jul;102(7):680-8. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/apa.12244> DOI: 10.1111/apa.12244
24. Benninger KL, Inder TE, Goodman AM, et al. Perspectives from the Society for Pediatric Research. Neonatal encephalopathy clinical trials: developing the future. *Pediatr Res*. 2021 Jan;89(1):74-84. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/32221474> DOI: 10.1038/s41390-020-0859-9
25. Scotland NEf. Scottish Neuroprotection Care Pathway (NCP) for infants with hypoxic-ischaemic encephalopathy (HIE) [Web page]. Scotland: TURAS; 2023 [cited February 2023]. Available from: <https://learn.nes.nhs.scot/62008>
26. Tagin MA, Woolcott CG, Vincer MJ, et al. Hypothermia for neonatal hypoxic ischemic encephalopathy: an updated systematic review and meta-analysis. *Arch Pediatr Adolesc Med*. 2012 Jun 1;166(6):558-66. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/22312166> DOI: 10.1001/archpediatrics.2011.1772
27. Bedetti L, Lugli L, Garetti E, et al. Sudden unexpected postnatal collapse and therapeutic hypothermia: what's going on? *Children (Basel)*. 2022 Dec 8;9(12). Available from: <https://pubmed.ncbi.nlm.nih.gov/36553368/> DOI: 10.3390/children9121925
28. Smit E, Liu X, Jary S, et al. Cooling neonates who do not fulfil the standard cooling criteria - short- and long-term outcomes. *Acta Paediatr*. 2015 Feb;104(2):138-45. DOI: 10.1111/apa.12784
29. NETS. Hypoxic ischaemic encephalopathy in the newborn - NETS practice guideline. Sydney: Sydney Children's Hospitals Network; 2022 [cited August 2022]. Available from: [https://www.schn.health.nsw.gov.au/\\_policies/pdf/2014-5005.pdf](https://www.schn.health.nsw.gov.au/_policies/pdf/2014-5005.pdf)
30. Strohm B, Hobson A, Brocklehurst P, et al. Subcutaneous fat necrosis after moderate therapeutic hypothermia in neonates. *Pediatrics*. 2011;128:e450. Available from: <https://pubmed.ncbi.nlm.nih.gov/21727110/> DOI: 10.1542/peds.2010-3508
31. Sagaser A, Pilon B, Goeller A, et al. Parent experience of hypoxic-ischemic encephalopathy and hypothermia: a call for trauma informed care. *Am J Perinatol*. 2022 2022/03/04(EFirst). Available from: <http://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1739-3388> DOI: 10.1055/a-1739-3388
32. Clinical Excellence Commission (CEC). Incidence management. Sydney: CEC; 2020. Available from: [https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/PD2020\\_047.pdf](https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/PD2020_047.pdf)
33. Chandrasekaran M, Chaban B, Montaldo P, et al. Predictive value of amplitude-integrated EEG (aEEG) after rescue hypothermic neuroprotection for hypoxic ischemic encephalopathy: a meta-analysis. *J Perinatol*. 2017 Jun;37(6):684-9. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/28252661> DOI: 10.1038/jp.2017.14

# Appendix: Changes in guidance since 2010 NSW Health Policy Directive PD 2010: 006

The clinical practice guide replaces the NSW Health Policy Directive, PD2010 006: Whole Body Cooling - Neonates Suspected Moderate or Severe Hypoxic Ischaemic Encephalopathy (HIE).<sup>1</sup>

Changes since 2010 include:

- Addition of Newborn Encephalopathy Pathway to assist in recognition of newborns with HIE.
- A recommendation for continuous monitoring and frequent review of newborns at high risk of HIE (Newborn Encephalopathy Red Pathway). The management should be in a neonatal unit and last at least six hours.
- The expansion of NSW Newborn Encephalopathy Severity Tool to include criteria for mild, moderate and severe encephalopathy and recording of seizures.
- Hourly neurological assessment from one to six hours after birth using the Assessment of Encephalopathy Severity Tool.
  - Minor changes to criteria for therapeutic hypothermia, including: need for only one feature of depression at birth in addition to (previously required two features).
  - Addition of option to use EEG or aEEG assessment to help determine moderate or severe encephalopathy.<sup>33</sup>
- Option for therapeutic hypothermia to be considered for newborns with moderate or severe encephalopathy and pH 7 to 7.1, or lactate  $\geq 8.0$  OR following post-natal collapse, when it is considered that hypoxia/ischaemia is the most likely cause of the encephalopathy.
- Introduction of the option for telehealth/video assessment with tertiary centres to aid in assessment of encephalopathy severity.

## Acknowledgements

The ACI acknowledges the contributions of the expert advisory group members in the development of this guide.

Dr Adam Buckmaster	Staff Specialist, Paediatrics	Central Coast LHD
Alison Goodfellow	Patient Safety Analyst, Maternal & Perinatal	Clinical Excellence Commission
Dr Daniel Challis	Senior Obstetric Advisor	NSW Ministry of Health
Dr Dharmintra Pasupathy	Professor of Maternal & Fetal Medicine	University of Sydney
Dr Hannah Dalrymple	Staff Specialist	NETS
Dr Harvey Lander	Director Systems Improvement	Clinical Excellence Commission
Jane Wardle	Nurse Manager, Special Care Nursery	Central Coast LHD
Dr Jennifer Bowen (Chair)	Senior Staff Specialist, Neonatology	Royal North Shore Hospital
Jo Davis	Improvement Lead, Maternity & Neonatal Safety Program	Clinical Excellence Commission
Joanne Sheils	Project Officer, Maternity & Neonatal Network	Agency for Clinical Innovation
Dr John Smyth	Staff Specialist, Neonatology	South Eastern Sydney LHD
Assoc Prof Koert de Waal	Staff Specialist, Neonatology	Hunter New England LHD
Malcolm Green	Senior Manager, Patient Safety Improvement Programs	Clinical Excellence Commission
Dr Mark Greenhalgh	Staff Specialist, Neonatology	Sydney LHD
Dr Melissa Luig	Staff Specialist, Neonatology	Western Sydney LHD
Morweena Williams	Patient Safety Analyst, Maternal & Perinatal	Clinical Excellence Commission
Dr Rakesh Seth	Neonatologist and Paediatrician	Murrumbidgee LHD
Dr Robert Guaran	Senior Neonatology Advisor	Ministry of Health
Sue Downward	Clinical Midwifery Consultant	Nepean Blue Mountains LHD
Trish Grant	Clinical Nurse Specialist	NETS
<b>External advisors</b>		
Dr Amanda Dyson	Staff Specialist, Neonatology	Canberra Hospital
Prof Rod Hunt	Neonatologist	Monash Children's Hospital

The Agency for Clinical Innovation (ACI) is the lead agency for innovation in clinical care.

We bring consumers, clinicians and health-care managers together to support the design, assessment and implementation of clinical innovations across the NSW public health system to change the way that care is delivered.

The ACI's clinical networks, institutes and taskforces are chaired by senior clinicians and consumers who have a keen interest and track record in innovative clinical care.

We also work closely with the Ministry of Health and the four other pillars of NSW Health to pilot, scale and spread solutions to healthcare system-wide challenges. We seek to improve the care and outcomes for patients by re-designing and transforming the NSW public health system.

Our innovations are:

- person-centred
- clinically led
- evidence-based
- value-driven.

[aci.health.nsw.gov.au](http://aci.health.nsw.gov.au)



AGENCY FOR  
**CLINICAL  
INNOVATION**

*Our vision is to create the future of healthcare,  
and healthier futures for the people of NSW.*